SlideShare uma empresa Scribd logo
1 de 128
acute renal failure … from basics to the latest advances Joel M. Topf, MD Clinical Nephrologist http://pbfluids.com
the house moment
Dr. Haas invented the first dialysis machine designed for humans and in 1928 he treated 6 patients.  All of them died.
In 1943, Willem Kolff’s, working in Nazi occupied Netherlands created the second human dialysis machine.  In 1943 he dialyzed his first patient, a young man with acute nephritis.  In 1945, a 67-year-old woman in uremic coma presented to Dr Kolff.                 Regained consciousness after 11 hours of hemodialysis.         Dr. Haas
[object Object],[object Object]
 
 
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object]
Same rise in creatinine. Same diagnosis: acute renal failure. Two completely different diseases. Two women. Same age. Same race.
definition of acute renal failure  ,[object Object],35   definitions
[object Object],biochemical  definitions
[object Object],[object Object],[object Object],[object Object],event driven definitions
 
 
R  isk I  njury F  ailure L  oss of function E  nd-Stage Renal disease rifle criteria for  stratifying arf
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
R  isk :  Inc Cr 50-100% or U.O. < 0.5 mL/kg/hr for > 6 hrs I  njury : Inc Cr 100-200% or U.O. < 0.5 mL/kg/hr > 12 hrs F  ailure : Inc Cr > 200% or > 4 mg/dL or U.O. < 0.3 mL/kg/hr > 24 hrs or anuria for more than 12 hours L  oss of function : Need for dialysis for more than 4 weeks E  nd-Stage Renal disease  : Need for dialysis for more than 3 months
nice criteria. do they work? ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Uchino S, Bellomo R, Goldsmith D. Crit Care Med 2006 Vol 34 1913-1917.
Hospital Mortality >3x BL Cr Cr > 4
nice criteria. do they work in the icu? ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Hoste E, Clermont G, Kersten A. Crit Care 2006 Vol 310
 
when Hoste looked at markers of severity of illness excluding the renal system: No survival difference between the 4 groups:  •  Lack of renal failure • Risk • Injury • Failure
RIFLE is dependent on creatinine. creatine is a functional marker of organ damage Functional markers: old  and busted
biomarkers are foot prints of actual organ damage Biomarkers,  new hotness
functional versus biomarkers Functional Marker Biomarker Liver damage Hypoalbuminemia Coagulopathy SGOT SGPT GGT
functional versus biomarkers Functional Marker Biomarker Liver damage Hypoalbuminemia Coagulopathy SGOT SGPT GGT Heart damage Hypotension Arrhythmia Troponin I Troponin T CK-MB
functional versus biomarkers Functional Marker Biomarker Liver damage Hypoalbuminemia Coagulopathy SGOT SGPT GGT Heart damage Hypotension Arrhythmia Troponin I Troponin T CK-MB Kidney damage Creatinine BUN Cystatin C KIM-1 NGAL
creatinine as a lagging indicator ,[object Object],[object Object],[object Object]
<0.5 0.4 0.2 0.1 0.3 0.5 0.7 0.9 Creatinine falls Creatinine rises Delta Creatinine (mg/dL)
candidates for a renal troponin:
[object Object],[object Object],[object Object],candidates for a renal troponin: kidney injury molecule-1 (kim-1) 2.00 0.34 0.13 0.69 Han WH, Bailly V, Abichandani. Kidney Int 2002 62, 237–244. Liangos O, Han WK, Wald R. Abstract J Am Soc Nephrol 16: 318A, 2005.
candidates for a renal troponin: kidney injury molecule-1 (kim-1) ,[object Object],[object Object],[object Object],Time starts at aorta cross clamp. Cr rose to 2.1. Han WH, Bailly V, Abichandani. Kidney Int 2002 62, 237–244. Liangos O, Han WK, Wald R. Abstract J Am Soc Nephrol 16: 318A, 2005.
urinary neutrophil gelatinase-associated lipocalin (ngal) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Mishra J, Ma Q, Prada A. J Am Soc Nephrol 2003; 14: 2534-43. Wagener G, Jan M, K M. Anesthesia 2006; 105: 485-91.
 
 
 
differential diagnosis
etiologies of arf ,[object Object],[object Object],[object Object],[object Object],[object Object]
Hou SH, Bushinsky DA, Wish JB. Am J Med 1983; 74: 243-8. Nash K, Hafeez A, Hou S. Am J Kidney Dis. 2002; 39: 930-6. Kaufman J, Dhakal M, Patel B, Et al. Am J Kidney Dis 1991; 17: 191-8.
Hou SH, Bushinsky DA, Wish JB. Am J Med 1983; 74: 243-8. Nash K, Hafeez A, Hou S. Am J Kidney Dis. 2002; 39: 930-6. Kaufman J, Dhakal M, Patel B, Et al. Am J Kidney Dis 1991; 17: 191-8.
N=103 N=256 N=389 Pascual J, Liano F. J Am Geriatr Soc 1998, 46: 1-5.
hospital acquired acute renal failure
hospital acquired acute renal failure
 
 
Pre-renal azotemia No BP, no pee pee
Pre-renal ARF ,[object Object],no bp, no pee pee RPF a u t o r e g u l a t i o n GFR
differentiation of prerenal from intrinsic renal disease ,[object Object],[object Object],[object Object]
 
Excreted Na Filtered Na Fractional excretion of sodium:
Excreted Na   = Urine Na x Urine Volume Calculating the Numerator
Filtered Na  = Serum Na x GFR Calculating the Denominator GFR =  Urine Cr x Urine Volume   Serum Cr Filtered Na  =  Serum Na x UrCr x UrVol   Serum Cr
Urine Na  x  Urine Volume Serum Na x UrCr x Urine Volume Serum Cr FENa = Excreted Na Filtered Na FENa = Urine Na Serum Na x UrCr   Serum Cr FENa = Urine Na x Serum Cr Serum Na x UrCr FENa =
FENa the easy way ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Sr Na Sr Cr x  Ur Na x  Ur Cr FENa  =
FeNa. what is it good for? ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Miller, Schrier, Et al. Annals Int Med, 1978 Vol 89. p 47-50 Pre-renal azotemia ATN (oliguric and non-oliguric) FENa < 1 27 4 FENa > 1 3 51 Pre-renal azotemia ATN (oliguric and non-oliguric) FENa > 1 3 51 FENa < 1 27 4
Low FENa, Not pre-renal ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],FENa False Positive
FeNa false negatives ,[object Object],[object Object],High FENa, but pre-renal
[object Object],[object Object],[object Object],[object Object],Low fractional excretion of sodium in acute renal failure Role of timing of the test and ischemia
fractional excretion of urea ,[object Object],[object Object],[object Object],[object Object],Kaplan, Kohn. American J Nephrol, 1992; 12: 49-54. Sr Na Sr Cr x  Ur Na x  Ur Cr FENa  = Sr Urea Sr Cr x  Ur Urea x  Ur Cr FEurea  =
 
 
FEurea in the differential diagnosis of atn ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Carvounis, Sabeeha, Nisar, Et al. Kidney Int, 2002 Vol 62. p 2223-2229
FENa FEUrea
therapy Renal replacement therapy Furosemide Dopamine Fenoldapam hANP (Anaritide)
renal replacement therapy
Dialysate Conventional Dialysis Diffusive Clearance 136 5.8 108 17 67 3.8 145 2 110 35 0 0
80 mmol K 5.8 mmol/L = 13.8 liters Isolated Ultrafiltration: CHF Solutions Minimal clearance 136 5.8 108 17 67 3.8 136 5.8 108 17 67 3.8
Ultrafilter 3+  liters/hour Replace all ultrafiltrate with sterile fluid at ideal plasma concentrations CVVH Convective clearance 136 5.8 108 17 67 3.8 140 2 108 30 0 0 140 4 108 30 0 0
Post-filter replacement fluid CVVH Convective clearance
Pre-filter replacement fluid CVVH Convective clearance
CVVHDF Convective and Diffusive
high dose dialysis survival Severity of illness (CCARF Score) High dose Low dose
Ronco’s landmark dialysis dose study ,[object Object],[object Object],[object Object],[object Object]
20 mL/kg/hr 35 mL/kg/hr 45 mL/kg/hr Ronco C, Bellomo R, Hormea P, Et al. Lancet 2000; 355: 26-30.
Schiffl: daily dialysis versus three days/wk dialysis ,[object Object],Schiffl, H. et al. N Engl J Med 2002;346:305-310 P=0.01 P=0.001
odds ratio of death Schiffl, H. et al. N Engl J Med 2002;346:305-310 P=0.002 P=0.005 P=0.007 P=0.02
adding dialysis to CVVH ,[object Object],[object Object],[object Object],P=0.03 P=0.008 Saudin P, Niederberger S, De Seigneux S, Et al. Kidney Int 2006; 70: 1312-7.
Ronco    425  CVVH  20/h vs. 35-45 ml/kg/h* Bouman   106  CVVH  20ml/kg/h* vs. 48 ml/kg/h Schiffl   160  Alternate day vs. daily hemodialysis Saudan    206  CVVH 25 ml/kg/h vs. CVVHDF 42 ml/kg/h Total (fixed effects) Total (random effects) 1 10 Odds ratio Study    n   treatment groups *For purposes of analysis the two high-dose arms in Ronco were combined, as were the two low-dose arms in Bouman. If these groups are removed the odds ratio is unchanged (1.94;  P  <0.001). Kellum J. Nature Clin Practice Nephrol 2007 3: 128-9.
 
ATN trial ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
interventions
endpoint ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
results 563 enrolled in standard care 561 randomized to intensive therapy
[object Object],[object Object],[object Object],[object Object],[object Object]
 
 
This report currently should be viewed as   the definitive study   defining dialysis dosing  in critically ill patients with AKI H. David Hume
… the  patient dies  from   multi-organ failure  while in  exquisite  electrolyte &  fluid balance .
Fluid balance?
[object Object],[object Object],[object Object],X 100
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],More fluid. More sick.
Worse fluid overload severity remained independently associated with mortality (OR, 1.03; 95% CI, 1.01-1.05). The relationship was satisfactorily linear and the OR suggests a  3% increase  in mortality  for each  1% increase   in degree of fluid overload  at CRRT initiation.
[object Object],[object Object],[object Object],[object Object],[object Object]
[in regards to the kidney]  these excretory operations are incidental to the major task of keeping our internal environments in the  ideal, balanced state . Homer Smith from Fish to Philosopher
Medical therapy of acute kidney injury  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
furosemide ,[object Object],[object Object]
Mehta’s trial of furosemide in arf ,[object Object],[object Object],Mehta, R. L. et al. JAMA 2002;288:2547-2553.
furosemide the rct ,[object Object],[object Object],[object Object],[object Object],[object Object],Cantarovich F, Rangoonwala B, Et al. Am J Kidney Dis 2004; 44: 402-9.
dopamine: still doesn’t work ,[object Object],[object Object],Increased RBF Increased urine
dopamine: still doesn’t work ,[object Object],[object Object],[object Object],ANZICS Clinical Trials Group. Lancet 2000;356:2139-47. Kellum JA, Decker JM.Crit Care 2001; 29:1526-31.
dopamine: still doesn’t work ,[object Object],[object Object],[object Object],[object Object],ANZICS Clinical Trials Group. Lancet 2000;356:2139-47. Kellum JA, Decker JM.Crit Care 2001; 29:1526-31.
dopamine: the randomized controlled trial ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],ANZICS Clinical Trials Group. Lancet 2000;356:2139-47.
[object Object],[object Object],[object Object],[object Object],[object Object]
meta-analysis ,[object Object],[object Object],Kellum JA, Decker JM.Crit Care 2001; 29:1526-31.
[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object]
complications of low-dose dopamine ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
dopamine 2.0: fenoldapam ,[object Object],[object Object],[object Object],[object Object],[object Object]
RCT of fenoldapam ,[object Object],[object Object],[object Object],[object Object],Tumlin JA, Finkel KW, Murray PT, Et al. Am J Kidney Dis. 2005; 46:26-34.
P=0.235 P=0.163 P=0.068 P=0.048 P=0.015 P=0.036 P=0.022 Tumlin JA, Finkel KW, Murray PT, Et al. Am J Kidney Dis. 2005; 46:26-34.
Tumlin JA, Finkel KW, Murray PT, Et al. Am J Kidney Dis. 2005; 46:26-34.
prophylactic fenoldapam in sepsis ,[object Object],[object Object],[object Object],[object Object]
Prophylaxis  is a way to get around the problem of late diagnosis due to the lack of an established biomarker.
P=0.006 P=0.056 Fenoldapam Placebo
atrial natriuretic peptide ,[object Object],[object Object],[object Object],[object Object]
radiocontrast nephropathy ,[object Object],[object Object],[object Object],[object Object],[object Object],Kurnik B, Allgren RL, Genter FC. Am J Kid Dis 1998; 31: 674-80.
[object Object],[object Object],[object Object],[object Object],Allgren R, Manbury T, Rahman SN. N Eng J Med 1997; 336: 828-34.  p =0.008
oliguric follow-up. strict EBM. ,[object Object],[object Object],Lewis J, Salem M, Chertow G. Am J Kid Dis 2000; 36: 767-74.  P=0.22 P=0.51 P<0.001
fixing everything that was wrong ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Swärd K, Valsson F, Odencrants P, Et al. Crit Care Med 2004; 32: 1310-5.
[object Object],[object Object],Swärd K, Valsson F, Odencrants P, Et al. Crit Care Med 2004; 32: 1310-5.
summary ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
summary ,[object Object],[object Object],[object Object],[object Object],[object Object]
Done

Mais conteúdo relacionado

Mais procurados

Mais procurados (20)

Delayed Graft Function post kidney transplant, Moh'd sharshir
Delayed Graft Function post kidney transplant, Moh'd sharshirDelayed Graft Function post kidney transplant, Moh'd sharshir
Delayed Graft Function post kidney transplant, Moh'd sharshir
 
International Society of Hypertension 2020 guidlines
International Society of Hypertension 2020 guidlinesInternational Society of Hypertension 2020 guidlines
International Society of Hypertension 2020 guidlines
 
Ckd
CkdCkd
Ckd
 
Managing DM and thyroid disease in shift workers
Managing DM and thyroid disease in shift workersManaging DM and thyroid disease in shift workers
Managing DM and thyroid disease in shift workers
 
Chronic Kidney Disease (CKD) - At a Glance - Dr. Gawad
Chronic Kidney Disease (CKD) - At a Glance - Dr. GawadChronic Kidney Disease (CKD) - At a Glance - Dr. Gawad
Chronic Kidney Disease (CKD) - At a Glance - Dr. Gawad
 
Is It Diabetic Nephropathy? (When to Biopsy?) - Dr. Gawad
Is It Diabetic Nephropathy? (When to Biopsy?) - Dr. GawadIs It Diabetic Nephropathy? (When to Biopsy?) - Dr. Gawad
Is It Diabetic Nephropathy? (When to Biopsy?) - Dr. Gawad
 
CKD Progression (Pharmacological Approach) - Dr. Gawad
CKD Progression (Pharmacological Approach) - Dr. GawadCKD Progression (Pharmacological Approach) - Dr. Gawad
CKD Progression (Pharmacological Approach) - Dr. Gawad
 
Medovahasrotodusti - Dyslipidemias
Medovahasrotodusti - DyslipidemiasMedovahasrotodusti - Dyslipidemias
Medovahasrotodusti - Dyslipidemias
 
PD in AKI
PD in AKIPD in AKI
PD in AKI
 
CKD (Pathogensis and Progression) - Dr. Gawad
CKD (Pathogensis and Progression) - Dr. GawadCKD (Pathogensis and Progression) - Dr. Gawad
CKD (Pathogensis and Progression) - Dr. Gawad
 
KDIGO CKD 2012
KDIGO CKD 2012KDIGO CKD 2012
KDIGO CKD 2012
 
KDIGO-Diabetes-2022-Guideline_Slide-Set-Update.pptx
KDIGO-Diabetes-2022-Guideline_Slide-Set-Update.pptxKDIGO-Diabetes-2022-Guideline_Slide-Set-Update.pptx
KDIGO-Diabetes-2022-Guideline_Slide-Set-Update.pptx
 
Diabetic Dyslipidemia Slide Share
Diabetic  Dyslipidemia Slide ShareDiabetic  Dyslipidemia Slide Share
Diabetic Dyslipidemia Slide Share
 
Aging kidney-structural-and-functional-changes ayman seddik
Aging kidney-structural-and-functional-changes ayman seddikAging kidney-structural-and-functional-changes ayman seddik
Aging kidney-structural-and-functional-changes ayman seddik
 
DCCT Landmark Trial
DCCT Landmark TrialDCCT Landmark Trial
DCCT Landmark Trial
 
IntraDialytic Hypertension (Basic Science → Evidence → Practice) - Dr. Gawad
IntraDialytic Hypertension (Basic Science → Evidence → Practice) - Dr. GawadIntraDialytic Hypertension (Basic Science → Evidence → Practice) - Dr. Gawad
IntraDialytic Hypertension (Basic Science → Evidence → Practice) - Dr. Gawad
 
Dyslipdemia Guidelines Head to Head
Dyslipdemia Guidelines Head to HeadDyslipdemia Guidelines Head to Head
Dyslipdemia Guidelines Head to Head
 
Diabetes management in hemodialysis by prof alaa wafa
Diabetes management in hemodialysis by prof alaa wafaDiabetes management in hemodialysis by prof alaa wafa
Diabetes management in hemodialysis by prof alaa wafa
 
Hemodialysis orders part 1
Hemodialysis orders part 1Hemodialysis orders part 1
Hemodialysis orders part 1
 
Role of SGLT2i in cardio-renal protection
Role of SGLT2i in cardio-renal protectionRole of SGLT2i in cardio-renal protection
Role of SGLT2i in cardio-renal protection
 

Destaque (6)

2 prismaflex crrt basic components - seg 2
2   prismaflex crrt basic components - seg 22   prismaflex crrt basic components - seg 2
2 prismaflex crrt basic components - seg 2
 
1 prismaflex crrt intro - seg 1 (2007)
1   prismaflex crrt intro - seg 1 (2007)1   prismaflex crrt intro - seg 1 (2007)
1 prismaflex crrt intro - seg 1 (2007)
 
CRRT workshop (Therapy overview I)
CRRT workshop (Therapy overview I)CRRT workshop (Therapy overview I)
CRRT workshop (Therapy overview I)
 
Kamc crrt training
Kamc crrt trainingKamc crrt training
Kamc crrt training
 
CRRT options in the ICU
CRRT options in the ICUCRRT options in the ICU
CRRT options in the ICU
 
3 prismaflex basic setup operation
3   prismaflex basic setup operation3   prismaflex basic setup operation
3 prismaflex basic setup operation
 

Semelhante a AKI Lecture 2010

02 Sperati Prevention And Management Of Acute Renal Failure
02 Sperati   Prevention And Management Of Acute Renal Failure02 Sperati   Prevention And Management Of Acute Renal Failure
02 Sperati Prevention And Management Of Acute Renal Failure
Dang Thanh Tuan
 
02 Sperati Prevention And Management Of Acute Renal Failure
02 Sperati   Prevention And Management Of Acute Renal Failure02 Sperati   Prevention And Management Of Acute Renal Failure
02 Sperati Prevention And Management Of Acute Renal Failure
guest2379201
 
Acute Kidney Injury
Acute Kidney InjuryAcute Kidney Injury
Acute Kidney Injury
Abhijit Nair
 
09 Nouri Acute Renal Failure
09 Nouri   Acute Renal Failure09 Nouri   Acute Renal Failure
09 Nouri Acute Renal Failure
guest2379201
 
09 Nouri Acute Renal Failure
09 Nouri   Acute Renal Failure09 Nouri   Acute Renal Failure
09 Nouri Acute Renal Failure
Dang Thanh Tuan
 
Hepatorenal syndrome
Hepatorenal syndromeHepatorenal syndrome
Hepatorenal syndrome
heyraghul
 
Acute Kidney Dysfunction
Acute Kidney DysfunctionAcute Kidney Dysfunction
Acute Kidney Dysfunction
Andrew Ferguson
 
What is teh nephrology power point presentation.pptx
What is teh nephrology power point presentation.pptxWhat is teh nephrology power point presentation.pptx
What is teh nephrology power point presentation.pptx
Dr.Jose Luis Rodriguez Lopez
 
21 Murphy Acute Renal Failure
21 Murphy   Acute Renal Failure21 Murphy   Acute Renal Failure
21 Murphy Acute Renal Failure
Dang Thanh Tuan
 
05 Goldstein Acute Renal Failure
05 Goldstein   Acute Renal Failure05 Goldstein   Acute Renal Failure
05 Goldstein Acute Renal Failure
guest2379201
 
How Best To Prevent & Manage Acute Renal failure
How Best To Prevent & Manage Acute Renal failureHow Best To Prevent & Manage Acute Renal failure
How Best To Prevent & Manage Acute Renal failure
chandra talur
 

Semelhante a AKI Lecture 2010 (20)

02 Sperati Prevention And Management Of Acute Renal Failure
02 Sperati   Prevention And Management Of Acute Renal Failure02 Sperati   Prevention And Management Of Acute Renal Failure
02 Sperati Prevention And Management Of Acute Renal Failure
 
02 Sperati Prevention And Management Of Acute Renal Failure
02 Sperati   Prevention And Management Of Acute Renal Failure02 Sperati   Prevention And Management Of Acute Renal Failure
02 Sperati Prevention And Management Of Acute Renal Failure
 
ARF No ATN Data
ARF No ATN DataARF No ATN Data
ARF No ATN Data
 
Acute kidney injury: Perioperative implications
Acute kidney injury: Perioperative implicationsAcute kidney injury: Perioperative implications
Acute kidney injury: Perioperative implications
 
Acute Kidney Injury
Acute Kidney InjuryAcute Kidney Injury
Acute Kidney Injury
 
29 amory renal failure
29 amory   renal failure29 amory   renal failure
29 amory renal failure
 
AKIforResidentsInternalMedicine2022.pptx
AKIforResidentsInternalMedicine2022.pptxAKIforResidentsInternalMedicine2022.pptx
AKIforResidentsInternalMedicine2022.pptx
 
09 Nouri Acute Renal Failure
09 Nouri   Acute Renal Failure09 Nouri   Acute Renal Failure
09 Nouri Acute Renal Failure
 
09 Nouri Acute Renal Failure
09 Nouri   Acute Renal Failure09 Nouri   Acute Renal Failure
09 Nouri Acute Renal Failure
 
Hepatorenal syndrome
Hepatorenal syndromeHepatorenal syndrome
Hepatorenal syndrome
 
Acute Kidney Dysfunction
Acute Kidney DysfunctionAcute Kidney Dysfunction
Acute Kidney Dysfunction
 
What is teh nephrology power point presentation.pptx
What is teh nephrology power point presentation.pptxWhat is teh nephrology power point presentation.pptx
What is teh nephrology power point presentation.pptx
 
Acute kidney injury
Acute kidney injuryAcute kidney injury
Acute kidney injury
 
Renal Failure
Renal FailureRenal Failure
Renal Failure
 
21 Murphy Acute Renal Failure
21 Murphy   Acute Renal Failure21 Murphy   Acute Renal Failure
21 Murphy Acute Renal Failure
 
05 Goldstein Acute Renal Failure
05 Goldstein   Acute Renal Failure05 Goldstein   Acute Renal Failure
05 Goldstein Acute Renal Failure
 
Dr ahmed alkodousi case
Dr ahmed alkodousi   caseDr ahmed alkodousi   case
Dr ahmed alkodousi case
 
Hemolytic Uremic Syndrome: A Dangerous Complication of E. coli
Hemolytic Uremic Syndrome: A Dangerous Complication of E. coliHemolytic Uremic Syndrome: A Dangerous Complication of E. coli
Hemolytic Uremic Syndrome: A Dangerous Complication of E. coli
 
How Best To Prevent & Manage Acute Renal failure
How Best To Prevent & Manage Acute Renal failureHow Best To Prevent & Manage Acute Renal failure
How Best To Prevent & Manage Acute Renal failure
 
17 february lupus nephritis prof ashraf fouda
17 february lupus nephritis prof ashraf fouda17 february lupus nephritis prof ashraf fouda
17 february lupus nephritis prof ashraf fouda
 

Mais de Joel Topf

Herbal toxins grand rounds feb 2014
Herbal toxins grand rounds feb 2014Herbal toxins grand rounds feb 2014
Herbal toxins grand rounds feb 2014
Joel Topf
 
Creatine supplements
Creatine supplementsCreatine supplements
Creatine supplements
Joel Topf
 
Imaging in Acute Kidney Injury, how not to harm patients
Imaging in Acute Kidney Injury, how not to harm patientsImaging in Acute Kidney Injury, how not to harm patients
Imaging in Acute Kidney Injury, how not to harm patients
Joel Topf
 
The Two Faces of Geriatric Kidney Disease
The Two Faces of Geriatric Kidney DiseaseThe Two Faces of Geriatric Kidney Disease
The Two Faces of Geriatric Kidney Disease
Joel Topf
 
Electrolyte Vignette
Electrolyte VignetteElectrolyte Vignette
Electrolyte Vignette
Joel Topf
 
The Kidney and HIV
The Kidney and HIVThe Kidney and HIV
The Kidney and HIV
Joel Topf
 

Mais de Joel Topf (20)

Hyperkalemia, an update
Hyperkalemia, an updateHyperkalemia, an update
Hyperkalemia, an update
 
Diabetic kidney disease
Diabetic kidney diseaseDiabetic kidney disease
Diabetic kidney disease
 
Low anion gap
Low anion gapLow anion gap
Low anion gap
 
Herbal toxins grand rounds feb 2014
Herbal toxins grand rounds feb 2014Herbal toxins grand rounds feb 2014
Herbal toxins grand rounds feb 2014
 
Acute Kidney Injury 2013
Acute Kidney Injury 2013Acute Kidney Injury 2013
Acute Kidney Injury 2013
 
Prescribing an app
Prescribing an appPrescribing an app
Prescribing an app
 
Creatine supplements
Creatine supplementsCreatine supplements
Creatine supplements
 
Social Media in Health Care
Social Media in Health CareSocial Media in Health Care
Social Media in Health Care
 
Imaging in Acute Kidney Injury, how not to harm patients
Imaging in Acute Kidney Injury, how not to harm patientsImaging in Acute Kidney Injury, how not to harm patients
Imaging in Acute Kidney Injury, how not to harm patients
 
Uric Acid, Fructose and Hypertension
Uric Acid, Fructose and HypertensionUric Acid, Fructose and Hypertension
Uric Acid, Fructose and Hypertension
 
Hyponatremia
HyponatremiaHyponatremia
Hyponatremia
 
Diabetic Nephropathy 2009
Diabetic Nephropathy 2009Diabetic Nephropathy 2009
Diabetic Nephropathy 2009
 
Osmolar Gap
Osmolar GapOsmolar Gap
Osmolar Gap
 
Sodium dreadnaught
Sodium dreadnaughtSodium dreadnaught
Sodium dreadnaught
 
Electrolyte Free Water Clearance
Electrolyte Free Water ClearanceElectrolyte Free Water Clearance
Electrolyte Free Water Clearance
 
The Two Faces of Geriatric Kidney Disease
The Two Faces of Geriatric Kidney DiseaseThe Two Faces of Geriatric Kidney Disease
The Two Faces of Geriatric Kidney Disease
 
Whats New In Potassium
Whats New In PotassiumWhats New In Potassium
Whats New In Potassium
 
Lead Time Bias
Lead Time BiasLead Time Bias
Lead Time Bias
 
Electrolyte Vignette
Electrolyte VignetteElectrolyte Vignette
Electrolyte Vignette
 
The Kidney and HIV
The Kidney and HIVThe Kidney and HIV
The Kidney and HIV
 

Último

Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
ZurliaSoop
 
1029-Danh muc Sach Giao Khoa khoi 6.pdf
1029-Danh muc Sach Giao Khoa khoi  6.pdf1029-Danh muc Sach Giao Khoa khoi  6.pdf
1029-Danh muc Sach Giao Khoa khoi 6.pdf
QucHHunhnh
 
Seal of Good Local Governance (SGLG) 2024Final.pptx
Seal of Good Local Governance (SGLG) 2024Final.pptxSeal of Good Local Governance (SGLG) 2024Final.pptx
Seal of Good Local Governance (SGLG) 2024Final.pptx
negromaestrong
 
The basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxThe basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptx
heathfieldcps1
 
Spellings Wk 3 English CAPS CARES Please Practise
Spellings Wk 3 English CAPS CARES Please PractiseSpellings Wk 3 English CAPS CARES Please Practise
Spellings Wk 3 English CAPS CARES Please Practise
AnaAcapella
 
Activity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfActivity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdf
ciinovamais
 

Último (20)

psychiatric nursing HISTORY COLLECTION .docx
psychiatric  nursing HISTORY  COLLECTION  .docxpsychiatric  nursing HISTORY  COLLECTION  .docx
psychiatric nursing HISTORY COLLECTION .docx
 
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
 
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptxSKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
 
Asian American Pacific Islander Month DDSD 2024.pptx
Asian American Pacific Islander Month DDSD 2024.pptxAsian American Pacific Islander Month DDSD 2024.pptx
Asian American Pacific Islander Month DDSD 2024.pptx
 
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
 
General Principles of Intellectual Property: Concepts of Intellectual Proper...
General Principles of Intellectual Property: Concepts of Intellectual  Proper...General Principles of Intellectual Property: Concepts of Intellectual  Proper...
General Principles of Intellectual Property: Concepts of Intellectual Proper...
 
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
 
ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.
 
microwave assisted reaction. General introduction
microwave assisted reaction. General introductionmicrowave assisted reaction. General introduction
microwave assisted reaction. General introduction
 
1029-Danh muc Sach Giao Khoa khoi 6.pdf
1029-Danh muc Sach Giao Khoa khoi  6.pdf1029-Danh muc Sach Giao Khoa khoi  6.pdf
1029-Danh muc Sach Giao Khoa khoi 6.pdf
 
Seal of Good Local Governance (SGLG) 2024Final.pptx
Seal of Good Local Governance (SGLG) 2024Final.pptxSeal of Good Local Governance (SGLG) 2024Final.pptx
Seal of Good Local Governance (SGLG) 2024Final.pptx
 
Introduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The BasicsIntroduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The Basics
 
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
 
How to Manage Global Discount in Odoo 17 POS
How to Manage Global Discount in Odoo 17 POSHow to Manage Global Discount in Odoo 17 POS
How to Manage Global Discount in Odoo 17 POS
 
SOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning PresentationSOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning Presentation
 
Python Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docxPython Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docx
 
The basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxThe basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptx
 
Application orientated numerical on hev.ppt
Application orientated numerical on hev.pptApplication orientated numerical on hev.ppt
Application orientated numerical on hev.ppt
 
Spellings Wk 3 English CAPS CARES Please Practise
Spellings Wk 3 English CAPS CARES Please PractiseSpellings Wk 3 English CAPS CARES Please Practise
Spellings Wk 3 English CAPS CARES Please Practise
 
Activity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfActivity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdf
 

AKI Lecture 2010

  • 1. acute renal failure … from basics to the latest advances Joel M. Topf, MD Clinical Nephrologist http://pbfluids.com
  • 3. Dr. Haas invented the first dialysis machine designed for humans and in 1928 he treated 6 patients. All of them died.
  • 4. In 1943, Willem Kolff’s, working in Nazi occupied Netherlands created the second human dialysis machine. In 1943 he dialyzed his first patient, a young man with acute nephritis. In 1945, a 67-year-old woman in uremic coma presented to Dr Kolff.                 Regained consciousness after 11 hours of hemodialysis.       Dr. Haas
  • 5.
  • 6.  
  • 7.  
  • 8.
  • 9.
  • 10. Same rise in creatinine. Same diagnosis: acute renal failure. Two completely different diseases. Two women. Same age. Same race.
  • 11.
  • 12.
  • 13.
  • 14.  
  • 15.  
  • 16. R isk I njury F ailure L oss of function E nd-Stage Renal disease rifle criteria for stratifying arf
  • 17.
  • 18.
  • 19.
  • 20.
  • 21.
  • 22. R isk : Inc Cr 50-100% or U.O. < 0.5 mL/kg/hr for > 6 hrs I njury : Inc Cr 100-200% or U.O. < 0.5 mL/kg/hr > 12 hrs F ailure : Inc Cr > 200% or > 4 mg/dL or U.O. < 0.3 mL/kg/hr > 24 hrs or anuria for more than 12 hours L oss of function : Need for dialysis for more than 4 weeks E nd-Stage Renal disease : Need for dialysis for more than 3 months
  • 23.
  • 24. Hospital Mortality >3x BL Cr Cr > 4
  • 25.
  • 26.  
  • 27. when Hoste looked at markers of severity of illness excluding the renal system: No survival difference between the 4 groups: • Lack of renal failure • Risk • Injury • Failure
  • 28. RIFLE is dependent on creatinine. creatine is a functional marker of organ damage Functional markers: old and busted
  • 29. biomarkers are foot prints of actual organ damage Biomarkers, new hotness
  • 30. functional versus biomarkers Functional Marker Biomarker Liver damage Hypoalbuminemia Coagulopathy SGOT SGPT GGT
  • 31. functional versus biomarkers Functional Marker Biomarker Liver damage Hypoalbuminemia Coagulopathy SGOT SGPT GGT Heart damage Hypotension Arrhythmia Troponin I Troponin T CK-MB
  • 32. functional versus biomarkers Functional Marker Biomarker Liver damage Hypoalbuminemia Coagulopathy SGOT SGPT GGT Heart damage Hypotension Arrhythmia Troponin I Troponin T CK-MB Kidney damage Creatinine BUN Cystatin C KIM-1 NGAL
  • 33.
  • 34. <0.5 0.4 0.2 0.1 0.3 0.5 0.7 0.9 Creatinine falls Creatinine rises Delta Creatinine (mg/dL)
  • 35. candidates for a renal troponin:
  • 36.
  • 37.
  • 38.
  • 39.  
  • 40.  
  • 41.  
  • 43.
  • 44. Hou SH, Bushinsky DA, Wish JB. Am J Med 1983; 74: 243-8. Nash K, Hafeez A, Hou S. Am J Kidney Dis. 2002; 39: 930-6. Kaufman J, Dhakal M, Patel B, Et al. Am J Kidney Dis 1991; 17: 191-8.
  • 45. Hou SH, Bushinsky DA, Wish JB. Am J Med 1983; 74: 243-8. Nash K, Hafeez A, Hou S. Am J Kidney Dis. 2002; 39: 930-6. Kaufman J, Dhakal M, Patel B, Et al. Am J Kidney Dis 1991; 17: 191-8.
  • 46. N=103 N=256 N=389 Pascual J, Liano F. J Am Geriatr Soc 1998, 46: 1-5.
  • 47. hospital acquired acute renal failure
  • 48. hospital acquired acute renal failure
  • 49.  
  • 50.  
  • 51. Pre-renal azotemia No BP, no pee pee
  • 52.
  • 53.
  • 54.  
  • 55. Excreted Na Filtered Na Fractional excretion of sodium:
  • 56. Excreted Na = Urine Na x Urine Volume Calculating the Numerator
  • 57. Filtered Na = Serum Na x GFR Calculating the Denominator GFR = Urine Cr x Urine Volume Serum Cr Filtered Na = Serum Na x UrCr x UrVol Serum Cr
  • 58. Urine Na x Urine Volume Serum Na x UrCr x Urine Volume Serum Cr FENa = Excreted Na Filtered Na FENa = Urine Na Serum Na x UrCr Serum Cr FENa = Urine Na x Serum Cr Serum Na x UrCr FENa =
  • 59.
  • 60.
  • 61.
  • 62.
  • 63.
  • 64.
  • 65.  
  • 66.  
  • 67.
  • 69. therapy Renal replacement therapy Furosemide Dopamine Fenoldapam hANP (Anaritide)
  • 71. Dialysate Conventional Dialysis Diffusive Clearance 136 5.8 108 17 67 3.8 145 2 110 35 0 0
  • 72. 80 mmol K 5.8 mmol/L = 13.8 liters Isolated Ultrafiltration: CHF Solutions Minimal clearance 136 5.8 108 17 67 3.8 136 5.8 108 17 67 3.8
  • 73. Ultrafilter 3+ liters/hour Replace all ultrafiltrate with sterile fluid at ideal plasma concentrations CVVH Convective clearance 136 5.8 108 17 67 3.8 140 2 108 30 0 0 140 4 108 30 0 0
  • 74. Post-filter replacement fluid CVVH Convective clearance
  • 75. Pre-filter replacement fluid CVVH Convective clearance
  • 77. high dose dialysis survival Severity of illness (CCARF Score) High dose Low dose
  • 78.
  • 79. 20 mL/kg/hr 35 mL/kg/hr 45 mL/kg/hr Ronco C, Bellomo R, Hormea P, Et al. Lancet 2000; 355: 26-30.
  • 80.
  • 81. odds ratio of death Schiffl, H. et al. N Engl J Med 2002;346:305-310 P=0.002 P=0.005 P=0.007 P=0.02
  • 82.
  • 83. Ronco 425 CVVH 20/h vs. 35-45 ml/kg/h* Bouman 106 CVVH 20ml/kg/h* vs. 48 ml/kg/h Schiffl 160 Alternate day vs. daily hemodialysis Saudan 206 CVVH 25 ml/kg/h vs. CVVHDF 42 ml/kg/h Total (fixed effects) Total (random effects) 1 10 Odds ratio Study n treatment groups *For purposes of analysis the two high-dose arms in Ronco were combined, as were the two low-dose arms in Bouman. If these groups are removed the odds ratio is unchanged (1.94; P <0.001). Kellum J. Nature Clin Practice Nephrol 2007 3: 128-9.
  • 84.  
  • 85.
  • 87.
  • 88. results 563 enrolled in standard care 561 randomized to intensive therapy
  • 89.
  • 90.  
  • 91.  
  • 92. This report currently should be viewed as the definitive study defining dialysis dosing in critically ill patients with AKI H. David Hume
  • 93. … the patient dies from multi-organ failure while in exquisite electrolyte & fluid balance .
  • 95.
  • 96.
  • 97. Worse fluid overload severity remained independently associated with mortality (OR, 1.03; 95% CI, 1.01-1.05). The relationship was satisfactorily linear and the OR suggests a 3% increase in mortality for each 1% increase in degree of fluid overload at CRRT initiation.
  • 98.
  • 99. [in regards to the kidney] these excretory operations are incidental to the major task of keeping our internal environments in the ideal, balanced state . Homer Smith from Fish to Philosopher
  • 100.
  • 101.
  • 102.
  • 103.
  • 104.
  • 105.
  • 106.
  • 107.
  • 108.
  • 109.
  • 110.
  • 111.
  • 112.
  • 113.
  • 114.
  • 115. P=0.235 P=0.163 P=0.068 P=0.048 P=0.015 P=0.036 P=0.022 Tumlin JA, Finkel KW, Murray PT, Et al. Am J Kidney Dis. 2005; 46:26-34.
  • 116. Tumlin JA, Finkel KW, Murray PT, Et al. Am J Kidney Dis. 2005; 46:26-34.
  • 117.
  • 118. Prophylaxis is a way to get around the problem of late diagnosis due to the lack of an established biomarker.
  • 120.
  • 121.
  • 122.
  • 123.
  • 124.
  • 125.
  • 126.
  • 127.
  • 128. Done

Notas do Editor

  1. Talk about the difficulty of using medline to differentiate the two conditions, imagine the difficulty of studying these patients in a trial for treatment for ARF Nephrology needed a language to describe ARF Similar to CKD where some people used the term CRI to describe a pt with a cr of 1.7 and other described a patient with a cr of 4.5 about to start dialysis
  2. An example of the former is contrast nephropathy where an event is defined by a 0.5 mg/dL or 25% increase in serum creatinine. The use of RRT to define ARF is often used in retrospective cohorts because it is easily gleaned from procedure codes and is unambiguous as well as unanimously perceived as an important end-point.
  3. An example of the former is contrast nephropathy where an event is defined by a 0.5 mg/dL or 25% increase in serum creatinine. The use of RRT to define ARF is often used in retrospective cohorts because it is easily gleaned from procedure codes and is unambiguous as well as unanimously perceived as an important end-point.
  4. An example of the former is contrast nephropathy where an event is defined by a 0.5 mg/dL or 25% increase in serum creatinine. The use of RRT to define ARF is often used in retrospective cohorts because it is easily gleaned from procedure codes and is unambiguous as well as unanimously perceived as an important end-point.
  5. Acute dialysis quality initiative (ADQI) Acute dialysis quality initiative (ADQI) Group of interested intensivists, nephrologists and industry representatives charged with publishing evidence based clinical practice guidelines Created a consensus definition of acute renal failure
  6. Acute dialysis quality initiative (ADQI)
  7. Acute dialysis quality initiative (ADQI)
  8. Acute dialysis quality initiative (ADQI)
  9. Acute dialysis quality initiative (ADQI)
  10. Acute dialysis quality initiative (ADQI)
  11. Acute dialysis quality initiative (ADQI)
  12. Acute dialysis quality initiative (ADQI)
  13. Suggesting the difference in mortality is accounted solely by the increasing severity of renal failure
  14. Paganini at Cleveland clinic retrospectively looked at dose of dialysis during ARF and compared it to survival stratified by Predicted mortality
  15. Primary outcome to
  16. Primary outcome to